Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

BACKGROUND: Preclinical data suggest cell cycle checkpoint blockade may induce an immunostimulatory tumor microenvironment. However, it remains elusive whether immunomodulation occurs in the clinical setting. To test this, we used blood and fresh tissue samples collected at baseline and post therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampert, Erika J, Cimino-Mathews, Ashley, Lee, Joo Sang, Nair, Jayakumar, Lee, Min-Jung, Yuno, Akira, An, Daniel, Trepel, Jane B, Ruppin, Eytan, Lee, Jung-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380948/
https://www.ncbi.nlm.nih.gov/pubmed/32709712
http://dx.doi.org/10.1136/jitc-2019-000516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380948/
https://www.ncbi.nlm.nih.gov/pubmed/32709712
http://dx.doi.org/10.1136/jitc-2019-000516

Ejemplares similares